Xanthinol nicotinate in the management of leg ulcers associated with haemoglobinopathies.
The therapeutic role of xanthinol nicotinate, with its potent action on the peripheral circulation, in promoting healing of leg ulcers when added to conservative measures of ulcer treatment in adult beta-thalassaemia major and sickle cell thalassaemia, was evaluated in a double-blind crossover trial in 16 patients suffering from multiple leg ulcers. Conservative measures of ulcer treatment were leg raising in horizontal position for 14 hours, bed-rest, local antiseptic dressings and antibiotics. Xanthinol nicotinate or placebo was administered in a daily dose of 8 tablets (2400 mg) for 10 weeks. Comparison of the treatment results of conservative measures plus xanthinol nicotinate and those of conservative measures plus placebo revealed a statistically significant higher rate of complete ulcer healing during xanthinol nicotinate therapy (p less than 0.01). Apart from a low incidence of generalized itching and flushing at the start of the trial, xanthinol nicotinate was well tolerated in the prescribed dose.
D000293:Adolescent; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006453:Hemoglobinopathies / Q000150:complications*; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D010919:Placebos; D013806:Theophylline / Q000031:analogs & derivatives*; D014971:Xanthinol Niacinate / Q000009:adverse effects / Q000627:therapeutic use*
D010919:Placebos; D014971:Xanthinol Niacinate; D013806:Theophylline